Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023

Rothschedl, E. and Wolf, S. (2022): Durvalumab (Imfinzi®) in combination with gemcitabine and cisplatin for the first‑line treatment of unresectable or metastatic biliary tract cancer (BTC). Update April 2023. Oncology Fact Sheet Nr. 116.

[thumbnail of Fact Sheet Nr.116_Update.pdf]

Preview

PDF - Sie müssen einen PDF-Viewer auf Ihrem PC installiert haben wie z. B. GSview, Xpdf oder Adobe Acrobat Reader
124kB

Item Type:	Horizon Scanning of Medicines
Subjects:	QV Pharmacology, toxicology, pharmacy > QV 60-370 Pharmacology QZ Pathology > QZ 200-380 Neoplasms.Cysts WB Practice of medicine > WB 300-962 Therapeutics WI Digestive system > WI 700-770 Liver. Billary tract
Language:	English
Series Name:	Oncology Fact Sheet Nr. 116
Deposited on:	07 Dec 2022 01:33
Last Modified:	28 Apr 2023 09:51

Repository Staff Only: item control page